

ALLAY, Aliskiren in Left Ventricular Hypertrophy; ALOFT, Aliskiren Observation of Heart Failure Treatment; ALTITUDE, The Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints; AMAZE, A Multicenter Trial Using Atacand and Zestril vs. Zestril to Evaluate the Effects on Lowering Blood Pressure; ASPIRE, Aliskiren Study in Post-MI Patients to Reduce Remodeling; AVANTE GARDE, Aliskiren and Valsartan to Reduce NT-proB-type natriuretic peptide (BNP) via Renin-Angiotensin-Aldosterone-System Blockade; AVOID, Aliskiren in Evaluation of Proteinuria in Diabetes; CALM, Candesartan and Lisinopril Microalbuminuria; CHARM, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity; IMPROVE, Irbesartan in the Management of PROteinuric patients at high risk for Vascular Events; ONTARGET, the Ongoing Telmisartan alone and in combination with Ramipril Global endpoint trial; RESOLVD, Randomized Evaluation of Strategies for Left Ventricular Dysfunction, VALERIA, Valsartan in combination with Lisinopril in Hypertensive patients with microalbuminuria; Val-HeFT, Valsartan Heart Failure Trial; VANTAGE, Valsartan in combination with Aliskiren compared to Valsartan alone in patients with Stage 2 Hypertension; V-HeFT, Vasodilator Heart Failure Trial.